Tenecteplase
Based on 1 Customer Validation
Tenecteplase (TNK-tPA) is a modified tissue plasminogen activator. Tenecteplase is a recombinant human tissue plasminogen activator (rt-PA) that has been bioengineered to produce mutations in three gene loci. Tenecteplase (TNK-tPA) can be used in the study of acute ischemic stroke.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 95.00%
- No. CAS: 191588-94-0
- Peso molecular:59.74 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
MCE Validation Data
In Vitro
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse ischemic thromboembolic models[3].
-
Dosage:0.25-2.5 mg/kg
-
Administration:iv, single dose
-
Result:Reduced infarct volume.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 191588-94-0
-
Appearance Liquid
-
Peso molecular 59.74 kDa
-
Color Colorless to light yellow
-
SMILES
[Tenecteplase]
-
Synonyms
TNK-tPA
-
Envío
Shipping with dry ice.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Kvistad CE, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol. 2022 Jun;21(6):511-519. [Content Brief]
[2]. Thelengana A, et al. Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis[J]. Acta Neurologica Belgica, 2019, 119: 359-367. [Content Brief]
[3]. Correa-Paz C, et al., Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke. J Cereb Blood Flow Metab. 2024 Aug;44(8):1306-1318. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tenecteplase Related Classifications
HY-108845 Related Classifications
Powered by Bioz